GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Avicanna Inc (TSX:AVCN) » Definitions » Interest Coverage

Avicanna (TSX:AVCN) Interest Coverage : 0 (At Loss) (As of Dec. 2023)


View and export this data going back to 2019. Start your Free Trial

What is Avicanna Interest Coverage?

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income by its Interest Expense. Avicanna's Operating Income for the three months ended in Dec. 2023 was C$-2.81 Mil. Avicanna's Interest Expense for the three months ended in Dec. 2023 was C$-0.15 Mil. did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is.

The historical rank and industry rank for Avicanna's Interest Coverage or its related term are showing as below:


TSX:AVCN's Interest Coverage is not ranked *
in the Drug Manufacturers industry.
Industry Median: 12.275
* Ranked among companies with meaningful Interest Coverage only.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.


Avicanna Interest Coverage Historical Data

The historical data trend for Avicanna's Interest Coverage can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Avicanna Interest Coverage Chart

Avicanna Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Interest Coverage
Get a 7-Day Free Trial - - - - -

Avicanna Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Interest Coverage Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Avicanna's Interest Coverage

For the Drug Manufacturers - Specialty & Generic subindustry, Avicanna's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Avicanna's Interest Coverage Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Avicanna's Interest Coverage distribution charts can be found below:

* The bar in red indicates where Avicanna's Interest Coverage falls into.



Avicanna Interest Coverage Calculation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:

If Interest Expense is negative and Operating Income is positive, then

Interest Coverage=-1* Operating Income /Interest Expense

Else if Interest Expense is negative and Operating Income is negative, then

The company did not have earnings to cover the interest expense.

Else if Interest Expense is 0 and Long-Term Debt & Capital Lease Obligation is 0, then

The company had no debt (1).


Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Avicanna's Interest Coverage for the fiscal year that ended in Dec. 2023 is calculated as

Here, for the fiscal year that ended in Dec. 2023, Avicanna's Interest Expense was C$-0.61 Mil. Its Operating Income was C$-8.38 Mil. And its Long-Term Debt & Capital Lease Obligation was C$0.10 Mil.

Avicanna did not have earnings to cover the interest expense.

Avicanna's Interest Coverage for the quarter that ended in Dec. 2023 is calculated as

Here, for the three months ended in Dec. 2023, Avicanna's Interest Expense was C$-0.15 Mil. Its Operating Income was C$-2.81 Mil. And its Long-Term Debt & Capital Lease Obligation was C$0.10 Mil.

Avicanna did not have earnings to cover the interest expense.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's Financial Strength is.


Avicanna  (TSX:AVCN) Interest Coverage Explanation

Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.

Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .


Avicanna Interest Coverage Related Terms

Thank you for viewing the detailed overview of Avicanna's Interest Coverage provided by GuruFocus.com. Please click on the following links to see related term pages.


Avicanna (TSX:AVCN) Business Description

Traded in Other Exchanges
Address
480 University Avenue, Suite 1502, Toronto, BC, CAN, M5G 1V2
Avicanna Inc is an innovative, commercial-stage, and international biopharmaceutical company focused on the development, advancement, and commercialization of evidence-based cannabinoid-based products for the global consumer, as well as medical and pharmaceutical market segments. In global cannabinoid advancements, it conducts most of its research in Canada at its research and development headquarters in JLABS in Toronto, located in the MaRS Discovery District. The company actively collaborates with Canadian academic and medical institutions. Avicanna has established a scientific platform including research and development and clinical development which led to the commercialization of more than twenty products across four main market segments.
Executives
Sheldon Inwentash 10% Security Holder

Avicanna (TSX:AVCN) Headlines

No Headlines